{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:51:34Z","timestamp":1793490694991,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.revmed.2022.05.009","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T19:56:10Z","timestamp":1654804570000},"page":"608-616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lymphomes spl\u00e9niques\u00a0: diagnostic et prise en charge"],"prefix":"10.1016","volume":"43","author":[{"given":"Q.","family":"Riller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cohen-Aubart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Roos-Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.revmed.2022.05.009_bib0335","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016\u00a0revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.revmed.2022.05.009_bib0340","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2010-09-271437","article-title":"How I diagnose and treat splenic lymphomas","volume":"117","author":"Iannitto","year":"2011","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.revmed.2022.05.009_bib0345","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hon.2399","article-title":"The 2016\u00a0updated WHO classification of lymphoid neoplasias","volume":"35","author":"Quintanilla-Martinez","year":"2017","journal-title":"Hematol Oncol"},{"issue":"12","key":"10.1016\/j.revmed.2022.05.009_bib0350","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/j.prp.2018.07.021","article-title":"Clinicopathological features of splenic tumours of lymphoid tissue","volume":"214","author":"Chen","year":"2018","journal-title":"Pathol Res Pract"},{"issue":"1","key":"10.1016\/j.revmed.2022.05.009_bib0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1155-1984(08)47141-8","article-title":"Lymphomes de la zone marginale","volume":"3","author":"Thieblemont","year":"2008","journal-title":"EMC - H\u00e9matologie"},{"issue":"1","key":"10.1016\/j.revmed.2022.05.009_bib0360","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/16078454.2019.1591570","article-title":"Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base","volume":"24","author":"Fallah","year":"2019","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.revmed.2022.05.009_bib0365","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3816\/CLM.2002.n.010","article-title":"Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81\u00a0patients","volume":"3","author":"Thieblemont","year":"2002","journal-title":"Clin Lymphoma"},{"issue":"5","key":"10.1016\/j.revmed.2022.05.009_bib0370","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654","article-title":"Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60\u00a0patients","volume":"100","author":"Chac\u00f3n","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.revmed.2022.05.009_bib0375","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.beha.2016.09.005","article-title":"Splenic marginal zone lymphoma","volume":"30","author":"Piris","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"issue":"17","key":"10.1016\/j.revmed.2022.05.009_bib0380","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2022.05.009_bib0385","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/00000441-196301000-00011","article-title":"The diagnostic significance of splenomegaly","volume":"245","author":"Schloesser","year":"1963","journal-title":"Am J Med Sci"},{"issue":"1","key":"10.1016\/j.revmed.2022.05.009_bib0390","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5694\/j.1326-5377.1986.tb113733.x","article-title":"A palpable spleen is not necessarily enlarged or pathological","volume":"145","author":"Arkles","year":"1986","journal-title":"Med J Aust"},{"issue":"4","key":"10.1016\/j.revmed.2022.05.009_bib0395","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0002-9629(15)41799-9","article-title":"Splenomegaly at a United States County Hospital: diagnostic evaluation of 170\u00a0patients","volume":"312","author":"O\u2019Reilly","year":"1996","journal-title":"Am J Med Sci"},{"issue":"2","key":"10.1016\/j.revmed.2022.05.009_bib0400","first-page":"78","article-title":"Splenomegaly in 2,505\u00a0patients in a large university medical center from 1913\u00a0to 1995. 1913\u00a0to 1962: 2,056\u00a0patients","volume":"169","author":"O\u2019Reilly","year":"1998","journal-title":"West J Med"},{"issue":"2","key":"10.1016\/j.revmed.2022.05.009_bib0405","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000040975","article-title":"Splenomegaly at a university hospital compared to a nearby county hospital in 317\u00a0patients","volume":"102","author":"Swaroop","year":"1999","journal-title":"Acta Haematol"},{"key":"10.1016\/j.revmed.2022.05.009_bib0410","doi-asserted-by":"crossref","first-page":"e0186674","DOI":"10.1371\/journal.pone.0186674","article-title":"Splenomegaly \u2013 Diagnostic validity, work-up, and underlying causes","volume":"12","author":"Rotbain","year":"2017","journal-title":"PLoS ONE [Internet]"},{"issue":"1","key":"10.1016\/j.revmed.2022.05.009_bib0415","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0035-9203(80)90019-X","article-title":"Massive splenomegaly in Northern Zambia. I.\u00a0Analysis of 344\u00a0cases","volume":"74","author":"Lowenthal","year":"1980","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"3","key":"10.1016\/j.revmed.2022.05.009_bib0420","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/ijlh.12212","article-title":"Leukocytosis","volume":"36","author":"Chabot-Richards","year":"2014","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"10.1016\/j.revmed.2022.05.009_bib0425","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3816\/CLM.2002.n.010","article-title":"Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81\u00a0patients","volume":"3","author":"Thieblemont","year":"2002","journal-title":"Clin Lymphoma"},{"issue":"8","key":"10.1016\/j.revmed.2022.05.009_bib0430","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3109\/10428194.2013.861067","article-title":"Long-term follow-up analysis of 100\u00a0patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment","volume":"55","author":"Lenglet","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.revmed.2022.05.009_bib0435","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/gepi.22242","article-title":"Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes","volume":"43","author":"Din","year":"2019","journal-title":"Genet Epidemiol"},{"key":"10.1016\/j.revmed.2022.05.009_bib0440","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semcancer.2013.12.001","article-title":"Lymphoma development in patients with autoimmune and inflammatory disorders\u00a0\u2013\u00a0What are the driving forces?","volume":"24","author":"Baecklund","year":"2014","journal-title":"Semin Cancer Biol"},{"issue":"8","key":"10.1016\/j.revmed.2022.05.009_bib0445","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","article-title":"Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium","volume":"111","author":"Smedby","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.revmed.2022.05.009_bib0450","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.revmed.2009.05.003","article-title":"[Splenic marginal zone lymphoma and autoimmunity: report of six cases]","volume":"31","author":"Voinchet","year":"2010","journal-title":"Rev Med Interne"},{"issue":"6","key":"10.1016\/j.revmed.2022.05.009_bib0455","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjh.13908","article-title":"High prevalence of splenic marginal zone lymphoma among patients with acquired C1\u00a0inhibitor deficiency","volume":"172","author":"Castelli","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.revmed.2022.05.009_bib0460","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjh.15063","article-title":"Frequent somatic mutations of KMT2D (MLL2) and CARD11\u00a0genes in primary cold agglutinin disease","volume":"183","author":"Ma\u0142ecka","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.revmed.2022.05.009_bib0465","first-page":"460","article-title":"Primary chronic cold agglutinin disease: a population based clinical study of 86\u00a0patients","volume":"91","author":"Berentsen","year":"2006","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.revmed.2022.05.009_bib0470","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.thromres.2014.08.021","article-title":"Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma","volume":"134","author":"Gebhart","year":"2014","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.revmed.2022.05.009_bib0475","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/ajh.21600","article-title":"Bone marrow biopsy in patients with hepatitis C virus infection: spectrum of findings and diagnostic utility","volume":"85","author":"Klco","year":"2010","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.revmed.2022.05.009_bib0480","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrclinonc.2009.169","article-title":"Gamma-delta T-cell lymphomas","volume":"6","author":"Tripodo","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.revmed.2022.05.009_bib0485","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1007\/s00261-018-1542-z","article-title":"18F-FDG PET\/CT in splenic marginal zone lymphoma","volume":"43","author":"Albano","year":"2018","journal-title":"Abdom Radiol N Y"},{"issue":"9","key":"10.1016\/j.revmed.2022.05.009_bib0490","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/RLU.0000000000000523","article-title":"Use of 18F-FDG PET\/CT imaging for evaluation of patients with primary splenic lymphoma","volume":"39","author":"Karunanithi","year":"2014","journal-title":"Clin Nucl Med"},{"issue":"9","key":"10.1016\/j.revmed.2022.05.009_bib0495","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1179\/1607845415Y.0000000005","article-title":"Role of blood and bone marrow examination in the diagnosis of mature lymphoid neoplasms in patients presenting with isolated splenomegaly","volume":"20","author":"Sreedharanunni","year":"2015","journal-title":"Hematology"},{"issue":"4","key":"10.1016\/j.revmed.2022.05.009_bib0500","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3324\/haematol.2009.011049","article-title":"CD5\u00a0expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24\u00a0cases","volume":"95","author":"Baseggio","year":"2010","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.revmed.2022.05.009_bib0505","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/PAS.0b013e318271243d","article-title":"Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology?","volume":"36","author":"Ponzoni","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1016\/j.revmed.2022.05.009_bib0510","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88\u00a0L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.revmed.2022.05.009_bib0515","first-page":"371","article-title":"Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma","volume":"2017","author":"Thieblemont","year":"2017","journal-title":"ASH Educ Program Book"},{"issue":"693","key":"10.1016\/j.revmed.2022.05.009_bib0520","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1259\/0007-1285-58-693-853","article-title":"Excision biopsy of the spleen by ultrasonic guidance","volume":"58","author":"Lindgren","year":"1985","journal-title":"Br J Radiol"},{"issue":"1","key":"10.1016\/j.revmed.2022.05.009_bib0525","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jvir.2007.08.025","article-title":"Percutaneous image-guided splenic biopsy in the oncology patient: an audit of 156\u00a0consecutive cases","volume":"19","author":"Tam","year":"2008","journal-title":"J Vasc Interv Radiol JVIR"},{"issue":"2","key":"10.1016\/j.revmed.2022.05.009_bib0530","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ajh.1085","article-title":"Ultrasound-guided fine needle biopsy of the spleen: high clinical efficacy and low risk in a multicenter Italian study","volume":"67","author":"Civardi","year":"2001","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.revmed.2022.05.009_bib0535","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.11110333","article-title":"Percutaneous image-guided biopsy of the spleen: systematic review and meta-analysis of the complication rate and diagnostic accuracy","volume":"260","author":"McInnes","year":"2011","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.revmed.2022.05.009_bib0540","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.amjsurg.2018.05.020","article-title":"The diagnostic value of splenectomy in patients without a definitive preoperative diagnosis","volume":"217","author":"Hangge","year":"2019","journal-title":"Am J Surg"},{"issue":"12","key":"10.1016\/j.revmed.2022.05.009_bib0545","first-page":"1348","article-title":"Hand-assisted laparoscopic splenectomy vs conventional laparoscopic splenectomy in cases of splenomegaly","volume":"137","author":"Rosen","year":"2002","journal-title":"Arch Surg Chic Ill 1960"},{"issue":"2","key":"10.1016\/j.revmed.2022.05.009_bib0550","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0002-9610(01)00874-1","article-title":"Laparoscopic splenectomy for massive splenomegaly","volume":"183","author":"Kercher","year":"2002","journal-title":"Am J Surg"},{"issue":"2","key":"10.1016\/j.revmed.2022.05.009_bib0555","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ajh.10253","article-title":"Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP)","volume":"72","author":"Schwartz","year":"2003","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.revmed.2022.05.009_bib0560","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/bjh.13320","article-title":"Outcomes in splenic marginal zone lymphoma: analysis of 107\u00a0patients treated in British Columbia","volume":"169","author":"Xing","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.revmed.2022.05.009_bib0565","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.revmed.2022.05.009_bib0570","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3109\/10428194.2015.1092529","article-title":"Peri-operative complications and hematologic improvement after first-line splenectomy for splenic marginal zone lymphoma","volume":"57","author":"Pata","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.revmed.2022.05.009_bib0575","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijsu.2017.03.077","article-title":"Still a role for surgery as first-line therapy of splenic marginal zone lymphoma? Results of a prospective observational study","volume":"41","author":"Pata","year":"2017","journal-title":"Int J Surg Lond Engl"},{"issue":"7","key":"10.1016\/j.revmed.2022.05.009_bib0580","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3109\/10428194.2013.845884","article-title":"Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?","volume":"55","author":"Kalpadakis","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.revmed.2022.05.009_bib0585","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjh.15641","article-title":"Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA\/IELSG36\u00a0study","volume":"183","author":"Iannitto","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.revmed.2022.05.009_bib0590","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s12253-009-9159-8","article-title":"Autoimmune hemolytic anemia as a risk factor of poor outcome in patients with splenic marginal zone lymphoma","volume":"15","author":"Fodor","year":"2009","journal-title":"Pathol Oncol Res"},{"issue":"6","key":"10.1016\/j.revmed.2022.05.009_bib0595","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3816\/CLM.2006.n.033","article-title":"Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia","volume":"6","author":"Fabbri","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"issue":"1","key":"10.1016\/j.revmed.2022.05.009_bib0600","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00277-009-0782-y","article-title":"Efficacy of rituximab in autoimmune hemolytic anemia associated with splenic marginal zone lymphoma","volume":"89","author":"Fozza","year":"2010","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.revmed.2022.05.009_bib0605","first-page":"2078","article-title":"Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies","volume":"15","author":"Dal Maso","year":"2006","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"issue":"2","key":"10.1016\/j.revmed.2022.05.009_bib0610","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4254\/wjh.v8.i2.107","article-title":"Hepatitis C virus and non-Hodgkin's lymphomas: meta-analysis of epidemiology data and therapy options","volume":"8","author":"Pozzato","year":"2016","journal-title":"World J Hepatol"},{"issue":"2","key":"10.1016\/j.revmed.2022.05.009_bib0615","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.revmed.2022.05.009_bib0620","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood-2005-09-3679","article-title":"Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation","volume":"107","author":"Suarez","year":"2006","journal-title":"Blood"},{"issue":"38","key":"10.1016\/j.revmed.2022.05.009_bib0625","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.3748\/wjg.v22.i38.8447","article-title":"Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma","volume":"22","author":"Merli","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.revmed.2022.05.009_bib0630","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/liv.14119","article-title":"Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: a systematic review and meta-analysis","volume":"39","author":"Masarone","year":"2019","journal-title":"Liver Int"},{"issue":"16","key":"10.1016\/j.revmed.2022.05.009_bib0635","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.revmed.2022.05.009_bib0640","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.revmed.2022.05.009_bib0645","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.revmed.2022.05.009_bib0650","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.revmed.2022.05.009_bib0655","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.revmed.2022.05.009_bib0330","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2016000976","article-title":"Combinations of idelalisib with rituximab and\/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma","volume":"1","author":"de Vos","year":"2016","journal-title":"Blood Adv"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866322005136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866322005136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:45:48Z","timestamp":1759337148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866322005136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":66,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0248866322005136"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2022.05.009","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphomes spl\u00e9niques\u00a0: diagnostic et prise en charge","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2022.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}